Possibilities of reducing the NSAID gastropathy risk in patients with osteoarthritis

V.N. Drozdov, E.V. Shikh, N.B. Lazareva

Sechenov University, Moscow

Osteoarthritis (OA) is a degenerative joint disease that primarily affects the articular cartilage. In OA, patients experience pain almost constantly, as the disease is based on inflammation. NSAIDs are one of the most commonly used classes of drugs in OA because they have anti-inflammatory and analgesic effects. However, with undeniable analgesic efficacy, NSAIDS have pronounced adverse events, including those in the gastrointestinal tract. It seems logical to prescribe complex anti-inflammatory therapy, which affects the disease pathogenesis, leads to a decrease in the pain component, as well as levels the adverse events in the gastric mucosa caused by the NSAIDs use. In this regard, it is worth noting the drug Alflutop, which has: many years of administration experience; proven clinical efficacy, confirmed in practice (both in reducing inflammation and pain component); patient-oriented pharmacological economical par t, which manifests itself in the subsequent reduction of the NSAIDs need; potential gastroprotective effect, confirmed in preclinical and clinical studies. All these arguments allow recommending Alflutop as a first-line drug from the SYSADOA group in patients with OA, especially those taking NSAIDs.

Keywords: osteoarthritis, NSAIDs, gastropathy, defect, ulcer, gastroprotection, preclinical study, laboratory animals, placebo-controlled clinical study.

For citation: Drozdov V.N., Shikh E.V., Lazareva N.B. Possibilities of reducing the NSAID gastropathy risk in patients with osteoarthritis. RMJ. 2019;12:74–78.